Update on Key Emerging Challenges in Cystic FibrosisMark T. Jennings, Michael Boyle, Kristin A. Riekert|Medical Principles and Practice|2014Cited by 3.7k
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>Claire Wainwright, Michael Boyle, Bonnie W. Ramsey et al.|New England Journal of Medicine|2015Cited by 1.6k
Multiattribute and Single-Attribute Utility Functions for the Health Utilities Index Mark 3 SystemDavid Feeny, Michael Boyle, William Furlong et al.|Medical Care|2002Cited by 1.3k
Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and NecrosisHarlan F. Weisman, Douglas T. Fearon, Michelle K. Leppo et al.|Science|1990Cited by 979
Inflammatory subtypes in asthma: Assessment and identification using induced sputumJodie L. Simpson, Peter G. Gibson, Rodney J. Scott et al.|Respirology|2006Cited by 939